TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02048241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Management Training
Description: This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Management Training
Description: This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Weekly dispensation of pills matching Intuniv but without the active medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intuniv
Description: Weekly administration of medication in doses as per protocol
Study: NCT02956902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician supported smartphone application intervention
Study: NCT00997113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: alfentanil 10 ug/kg immediately prior to propofol dose
Study: NCT02815826

Intervention type: OTHER
Intervention: Barefoot training
Description: During 16 weeks, habitual shod runners kept their normal running training routine (wearing shoes), while they were introduced progressively to BF condition. Three training sessions were performed per week. Barefoot training started with 5% and ended with 20% of their WTV being performed without shoes. Soft surfaces (i.e. sand and grass) were adopted in the beginning of training (week 1 to 8). From week 9 to 16, participants mixed soft with harder surfaces, as treadmill and asphalt, to accomplish the training.

Intervention type: OTHER
Intervention: Shod training
Description: Running training planned individually to each runner, according to their physical fitness, and performed with shoes.
Study: NCT02820961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entinostat
Description: An orally available histone deacetylases inhibitor (HDAC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entinostat
Description: An orally available histone deacetylases inhibitor (HDAC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Aromatase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Aromatase inhibitor
Study: NCT00632580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraarticular injection with ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extraarticular injection with ropivacaine
Study: NCT01159262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl/Morphine
Description: Per package insert, N-PASS scores and investigator discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl/Morphine
Description: Per package insert, N-PASS scores and investigator discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl/Morphine
Description: Per package insert, N-PASS scores and investigator discretion.
Study: NCT01252693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozarelix
Description: Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
Study: NCT02035306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non invasive co-oximetry haemaglobin measurement
Study: NCT02767362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Once enrolled on this pre-operative window study, patients with endometrial cancer will be treated with the standard clinical dose of atorvastatin (80 mg once daily orally) for an average of 2-4 weeks prior to surgical staging. Patients will need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging.
Study: NCT04365101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-001
Description: CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
Study: NCT03557632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cue Exposure Therapy
Description: As above.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention Drug Education
Description: As above.
Study: NCT01021670

Intervention type: DRUG
Intervention: Dapoxetine hydrochloride
Description: One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks

Intervention type: OTHER
Intervention: Alternate care/non-dapoxetine hydrochloride treatment(s)
Description: As prescribed or directed
Study: NCT02778815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kindness for Mums
Study: NCT06362772

Intervention type: RADIATION
Intervention: Iodine-125 brachytherapy
Description: In advance of the surgery, patients were informed about their condition, the expected efficacy of 125I seed implantation therapy, alternative treatments such as external beam radiotherapy and chemotherapy, as well as potential side effects and toxic effects. The preoperative evaluation process includes assessments of coagulation function, liver and kidney function, cardiopulmonary function, and local CT scans.~A collaborative effort between physicians and physicists was undertaken to establish a treatment regimen with a prescription dose ranging from 80 to 120 Gy. The patient accepted the treatment plan and signed an informed consent form. The CT-guided 125I seed implantation procedure was conducted according to the prescribed treatment regimen.~Efficacy evaluations were conducted at pre-surgery, 1-, 3-, and 5-month post-surgery. The evaluations focused on lesion dimensions, serum Tg, TGAb, TSH levels, pain levels, and adverse reactions.
Study: NCT01324193

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pomegranate extracts
Description: a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pomegranate extracts
Description: a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.
Study: NCT02308722

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5-fraction stereotactic body radiation therapy
Description: The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.~Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.~Level -1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 8Gy/# (total dose 40Gy)~Level 1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 9Gy/# (total dose 45Gy)~Level 2:~Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV_R) 9.5Gy/# (total dose 47.5Gy)~Level 3:~Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV_R) 10Gy/# (total dose 50Gy)
Study: NCT02121886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venous reconstruction with the parietal peritoneum
Study: NCT01746017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as capsules
Study: NCT04365101

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CYNK-001
Description: CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
Study: NCT04457388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Yoga Therapy
Description: Yoga practices combining with joint loosening exercises (Sukshma Vyayama), postures (Asana), breathing exercises (Pranayama), relaxation techniques and chanting ( A, U, M, and AUM { ૐ}) syllable chants meditation. Each session ended with home practice exercises given to the participants to practice everyday.
Study: NCT02588001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
Study: NCT02823444

Intervention type: OTHER
Intervention: Magnetic Resonance Angiography
Description: Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational.

Intervention type: OTHER
Intervention: Magnetic Resonance Angiography
Description: Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational.
Study: NCT02821663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vocal intervention
Description: 10 x 60 min. sessions of vocal intervention
Study: NCT03044574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCD
Description: Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GCS
Description: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GCS
Description: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH
Description: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
Study: NCT00890045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeRO Vascular Access Device
Description: HeRO Vascular Access Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ePTFE hemodialysis graft
Description: Conventional ePTFE hemodialysis graft
Study: NCT02166177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous regulatory T cell product
Description: Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
Study: NCT02390791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced myADHDportal.com
Description: Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual standard portal
Description: Standard version of myADHDportal.com web software
Study: NCT03971877

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid Polymyxin NP test
Description: From rectal swabs of patients admitted in ICU and oncohaematology ward, investigators will use first a new culture medium (SuperPolymyxin) for screening the colistin resistant Gram negative and then a new rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth micro-dilution (BMD) method.
Study: NCT02986776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Care
Description: 21 days of outpatient substance misuse treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Care
Description: 21 days of outpatient substance misuse treatment
Study: NCT02827968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN035
Description: KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
Study: NCT01909102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-based intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual care
Study: NCT01746017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2922470
Description: Administered orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2922470
Description: Administered orally as capsules
Study: NCT00501345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg by mouth on Day 1 only, followed by 160 mg by mouth daily
Study: NCT02321566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Motor Cortex Stimulation
Study: NCT01159262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT00193804

Intervention type: RADIATION
Intervention: IMRT
Description: IMRT in cervical cancers
Study: NCT01159262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT04657848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal gastrectomy combined with Cheng's Giraffe reconstruction
Description: proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
Study: NCT00867750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioembolisation (SIR-Spheres® microspheres)
Description: Yttrium-90 SIR-Spheres microspheres

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolisation
Description: TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
Study: NCT03796403

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac
Description: Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
Study: NCT02278783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
Study: NCT05462184

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Study: NCT01499290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ-AVI
Description: Ceftazidime 2000 mg and 500 mg of avibactam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 500 mg of Metronidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 gram of Meropenem
Study: NCT03365388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Description: Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerzhi
Description: Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
Study: NCT00550498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
Study: NCT04106414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS- 986205
Description: BMS-986205 100 mg every 4 weeks.
Study: NCT02972476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide & formoterol fumarate and Aclidinium bromide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 500 & salmeterol and Aclidinium bromide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 250 & salmeterol and Aclidinium bromide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium bromide & formoterol fumarate
Study: NCT04240678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic HBV Alert
Description: Electronic HBV Alert deployed in electronic medical charts of at risk patients
Study: NCT04223492

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liquid biopsy
Description: A blood sample containing circulating tumor DNA and circulating tumor cells.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multi-parametric MRI
Description: Multi-parametric MRI combines different imaging protocols in one session to measure more functional items than perfusion alone, addressing different aspects of tumor biology.
Study: NCT03625908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-guided PCI
Description: Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
Study: NCT03681223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertessa® Lite Y mesh
Description: Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restorelle® Y mesh
Description: Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sacrocolpopexy
Description: The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy
Description: The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation